We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.28B
AUM Growth
-$1.41B
Cap. Flow
-$1.19B
Cap. Flow %
-22.61%
Top 10 Hldgs %
53.54%
Holding
466
New
23
Increased
24
Reduced
24
Closed
360

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$72.5M
2
LEGN icon
Legend Biotech
LEGN
+$64.3M
3
OSCR icon
Oscar Health
OSCR
+$64.1M
4
DVAX
Dynavax Technologies
DVAX
+$62.6M
5
INDV icon
Indivior Pharmaceuticals
INDV
+$39M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$187M
2
KURA icon
Kura Oncology
KURA
+$106M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$66.5M
4
SGRY icon
Surgery Partners
SGRY
+$57.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$56.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Industrials 0.23%
3 Consumer Staples 0.01%
4 Energy 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
251
Insmed
INSM
$22.4B
– –
-52,861
Closed -$3.86M
IRMD icon
252
iRadimed
IRMD
$1.2B
– –
-7,137
Closed -$359K
J icon
253
Jacobs Solutions
J
$16B
– –
-1,778
Closed -$230K
JCI icon
254
Johnson Controls International
JCI
$85.1B
– –
-13,530
Closed -$1.05M
JOE icon
255
St. Joe Company
JOE
$3.55B
– –
-24,428
Closed -$1.42M
KALV
256
DELISTED
KalVista Pharmaceuticals
KALV
– –
-13,255
Closed -$153K
KBR icon
257
KBR
KBR
$4.56B
– –
-13,173
Closed -$858K
KEY icon
258
KeyCorp
KEY
$23.8B
– –
-10,252
Closed -$172K
KIDS icon
259
OrthoPediatrics
KIDS
$513M
– –
-17,897
Closed -$485K
NXDR
260
Nextdoor Holdings
NXDR
$885M
– –
-20,586
Closed -$51.1K
KLAC icon
261
KLA
KLAC
$222B
– –
-2,990
Closed -$232K
KLIC icon
262
Kulicke & Soffa
KLIC
$4.34B
– –
-21,531
Closed -$972K
KMB icon
263
Kimberly-Clark
KMB
$37.6B
– –
-5,157
Closed -$734K
KNSL icon
264
Kinsale Capital Group
KNSL
$8.58B
– –
-945
Closed -$440K
KRYS icon
265
Krystal Biotech
KRYS
$10.7B
– –
-4,166
Closed -$758K
KSS icon
266
Kohl's
KSS
$2.16B
– –
-16,877
Closed -$356K
KURA icon
267
Kura Oncology
KURA
$793M
– –
-5,411,571
Closed -$106M
KWR icon
268
Quaker Houghton
KWR
$2.58B
– –
-4,935
Closed -$831K
LDOS icon
269
Leidos
LDOS
$14.4B
– –
-1,814
Closed -$296K
LEA icon
270
Lear
LEA
$7.39B
– –
-11,067
Closed -$1.21M
LECO icon
271
Lincoln Electric
LECO
$14.1B
– –
-3,664
Closed -$704K
LFMD icon
272
LifeMD
LFMD
$176M
– –
-241,329
Closed -$1.26M
LFST icon
273
Lifestance Health
LFST
$4.15B
– –
-64,787
Closed -$454K
LNC icon
274
Lincoln National
LNC
$7.92B
– –
-13,586
Closed -$428K
LOW icon
275
Lowe's Companies
LOW
$121B
– –
-5,913
Closed -$1.6M
9 10
11
12 13

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2024 Portfolio in Review

As of Q4 2024, Deerfield Management held 466 positions worth $5.28B, down 21% from $6.69B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $1.19B in Q4 2024, closing 360 positions and reducing 24 holdings. Its most notable exit was Kura Oncology, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Deerfield Management opened a new position in Legend Biotech worth $50.5M.

  • Deerfield Management's largest Q4 2024 buy was Legend Biotech: 1,551,718 shares worth $50.5M.
  • Deerfield Management added most to NewAmsterdam Pharma in Q4 2024, an estimated $72.5M increase.
  • Deerfield Management's biggest Q4 2024 reduction was Nuvalent, cutting an estimated $187M.
  • Deerfield Management fully exited Kura Oncology in Q4 2024, selling an estimated $106M.
  • Deerfield Management's ten largest holdings make up 54% of its $5.28B portfolio in Q4 2024.
  • Deerfield Management opened 23 new positions and closed 360 in Q4 2024.
  • Deerfield Management's portfolio value fell 21% quarter-over-quarter to $5.28B.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.